NCT01749371 is a Phase 2/Phase 3 clinical trial of Vitamin E in Burn, sponsored by The University of Texas Medical Branch, Galveston.

Who is sponsoring NCT01749371?

NCT01749371 is sponsored by The University of Texas Medical Branch, Galveston.

What drugs are being tested in NCT01749371?

Interventions in NCT01749371: Vitamin E.

Is NCT01749371 still recruiting?

NCT01749371 is currently completed. Last updated 17 January 2019.

Last reviewed 2019-01-17 · How we verify

NCT01749371

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin E Supplementation in Burned Patients

Completed Phase 2/Phase 3 Last updated 17 January 2019

What this trial tests

Phase 2/Phase 3 trial testing Vitamin E in Burn in 31 participants. Completed in 1 September 2017.

Timeline

1 February 2013

Primary endpoint
1 August 2017

1 September 2017

Quick facts

Lead sponsor	The University of Texas Medical Branch, Galveston
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	1 February 2013
Primary completion	1 August 2017
Estimated completion	1 September 2017
Sites	3 locations across United States

Drugs / interventions tested

Vitamin E (VITAMIN E) — full drug profile →

Conditions studied

Burn — all drugs for Burn →

Sponsor

The University of Texas Medical Branch, Galveston

Who can join

Adults 16 to 85, any sex, with Burn. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Plasma Alpha- and Gamma-Tocopherol
Time frame: Days 0-30
Plasma measurements of alpha- and gamma-tocopherol as an indicator of antioxidant status

Sponsor's own description

A dietary antioxidant, alpha-tocopherol, will be used to potentially attenuate Vitamin E short- and long-term losses in plasma and adipose, reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of burn injury, including lung injury and impaired wound healing. This may improve the quality of life of the burn patient by preventing pathophysiology that may result from oxidative stress and may reduce hospital stay. Our research will lay the foundation for the future development of effective, safe, and economic therapeutic interventions to treat burn injury-associated metabolic abnormalities. Also, it will provide the basis for the development of supplemental regulations and pharmacotherapy to treat burn patients with vitamin E. The risks are very reasonable in relation to the anticipated benefits to our subjects because a) vitamin E is a simple vitamin that is abundant and approved for clinical use, and b) the subjects will be monitored consistently for the minimal increased tendency to bleed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vitamin E

Trials testing the same drug.

NCT07331103 — RESOLving INflammation Through Diet for Health (RESOLVIN) · NA · recruiting
NCT06081257 — The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve · NA · unknown
NCT05616442 — Ketotifen in Non-Alcoholic Fatty Liver Disease Patients · Phase 4 · completed
NCT06211478 — Role of Vitamin E in Gaucher Disease Patients · Phase 3 · completed
NCT04801849 — Vitamin E Dosing Study · Phase 2 · completed

Other recruiting trials for Burn

Currently open trials in the same condition.

NCT07221903 — The Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA · recruiting
NCT06992895 — The Effect of Hologram Application on Pain, Anxiety, and Fear Levels in Children During Burn Dressing · NA · recruiting
NCT07453927 — Blue Light for Donor Site Healing in Burn Patients · NA · recruiting
NCT07025408 — Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns · Phase 2 · recruiting

Other The University of Texas Medical Branch, Galveston trials

Trials by the same sponsor.

NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01749371 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
Last refreshed: 17 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01749371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing